<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22117594</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-6166</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Dec</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Central nervous system agents in medicinal chemistry</Title>
          <ISOAbbreviation>Cent Nerv Syst Agents Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.</ArticleTitle>
        <Pagination>
          <StartPage>305</StartPage>
          <EndPage>320</EndPage>
          <MedlinePgn>305-20</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent upon the degeneration of mesencephalic dopaminergic neurons. The therapeutic efficacy of L-DOPA has been related to its ability to restore dopamine (DA) extracellular levels in the Parkinsonian brain. The origin of the L-DOPA-induced rise in DA has been the object of numerous studies and controversies but the data collectively point to serotonergic (5-HT) neurons as being most significant in the release. Here, we review biochemical and behavioral evidence supporting serotonergic neurons as playing the main role in the actions of L-DOPA, considered from two points of view. The main aspect concerns the biochemical demonstration that 5-HT neurons are almost solely implicated in the release of DA induced by L-DOPA. The mechanism of action of L-DOPA inside 5-HT neurons will be thoroughly dissected on the basis of L-DOPA effects on extracellular versus tissue DA levels. The unique contribution of 5-HT neurons in mediating the release of newly synthesised DA from L-DOPA will be discussed in parallel with DA-dependent behaviors induced by L-DOPA. The other, and neglected, aspect concerns the possible deleterious impact of the presence of L-DOPA inside 5-HT neurons on 5-HT neuronal function. Overall, the fact that 5-HT neurons release the newly synthesised DA from L-DOPA in multiple brain regions beyond the striatum gives new insight into the large impact of L-DOPA in the Parkinsonian brain and strengthens therapeutic perspectives targeting the 5-HT system to reduce both motor and non-motor complications of L-DOPA medication.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Navailles</LastName>
            <ForeName>Sylvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Bordeaux, Unité Mixte de Recherche Centre National de la Recherche Scientifique 5293, 33076 Bordeaux cedex, France. sylvia.navailles@u-bordeaux2.fr</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carta</LastName>
            <ForeName>Manolo</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guthrie</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Deurwaerdère</LastName>
            <ForeName>Philippe</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Cent Nerv Syst Agents Med Chem</MedlineTA>
        <NlmUniqueID>101269163</NlmUniqueID>
        <ISSNLinking>1871-5249</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>333DO1RDJY</RegistryNumber>
          <NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>46627O600J</RegistryNumber>
          <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VTD58H1Z2X</RegistryNumber>
          <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059326" MajorTopicYN="N">Serotonergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2011</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22117594</ArticleId>
        <ArticleId IdType="doi">10.2174/1871524911106040305</ArticleId>
        <ArticleId IdType="pii">BSP/CNSAMC/E-Pub/# 46</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
